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ABSTRACT
A set of adenosine 3':5'-monophosphate (cAMP) analogues that com
bine exocyclic sulfur substitutions in the equatorial (Rp) or the axial (Sp)
position of the cyclophosphate ring with modifications in the adenine
base of cAMP were tested for their effect on the growth of HL-60 human
promyelocytic leukemia cells and LS-174T human colon carcinoma cells.
Both diastereomers of the phosphorothioate derivatives were growth
inhibitory, exhibiting a concentration inhibiting 50% of cell proliferation
of 3-100 AIM.Among the analogues tested, Rp-8-Cl-cAMPS and Sp-8-
Br-cAMPS were the two most potent. Rp-8-Cl-cAMPS was 5- to 10-fold
less potent than 8-Cl-cAMP while Sp-8-Br-cAMPS was approximately
6-fold more potent than 8-Br-cAMP. The growth inhibition was not due
to a block in a specific phase of the cell cycle or due to cytotoxicity. Rp-
8-CI-cAMPS enhanced its growth-inhibitory effect when added together
with 8-Cl-cAMP and increased differentiation in combination with V-
benzyl-cAMP. The binding kinetics data showed that these Sp and Rp
modifications brought about a greater decrease in affinity for Site B than
for Site A of RI (the regulatory subunit of type 1 cAMP-dependent
protein kinase) and a substantial decrease of affinity for Site A of RII
(the regulatory subunit of type II protein kinase) but only a small decrease
in affinity for Site B of RII, indicating the importance of the Site B
binding of RII in the growth-inhibitory effect. These results show that
the phosphorothioate analogues of i AM P are useful tools to investigate
the mechanism of action of cAMP in growth control and differentiation
and may have practical implication in the suppression of malignancy.
INTRODUCTION
cAMP- in mammalian cells acts through its receptor protein,
cAMP-dependent protein kinase (1, 2). There are two general
types of cAMP-dependent protein kinase, designated as type I
and type II, that contain distinct regulatory subunits, RI and
RII, respectively, but share a common catalytic subunit (3).
It has been shown (4-6) that differential regulation of type I
versus type II protein kinase is critically related to the growth-
inhibitory effect of site-selective cAMP analogues. Namely, the
potency of site-selective cAMP analogues in growth inhibition
correlates with a marked down-regulation of type I protein
kinase along with an up-regulation of type II protein kinase (7,
8). Unlike parent cAMP, site-selective cAMP analogues dem
onstrate selective binding toward either one of the two known
cAMP binding sites, [Site A (Site 2) and Site B (Site 1)] (9, 10),
of protein kinase, resulting in preferential binding and activa
tion of either protein kinase isozymes (11, 12). The striking
growth-inhibitory effect of 8-Cl-cAMP (13) is in fact related to
its selective binding and activation of protein kinase isozymes.
It binds to type II protein kinase with a high affinity for Site B
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but with a low affinity for Site A, keeping this isozyme in
holoenzyme form while binding with moderately high affinity
for both Site A and Site B to type I protein kinase, facilitating
the RI subunit dissociation and down-regulation of this isozyme
(6, 8).
Rp-cAMPS, which has a single sulfur substitution for the
exocyclic equatorial oxygen, acts as antagonist of cAMP-in-
duced activation of cAMP-dependent protein kinase, while Sp-
cAMPS, which has a single sulfur substitution in the exocyclic
axial oxygen position, acts as a cAMP agonist (14-16). Previous
studies have shown (16) that the antagonist binds to both type
I and type II protein kinase holoenzyme and locks the R
subunits in a configuration that has a high affinity for the
catalytic subunit, thus preventing activation of the holoenzyme.
The selectivity of phosphorothioates for the two different
cAMP binding sites has also been addressed (17). Dostmann et
al. (18) showed that for type I protein kinase, Sp and Rp forms
of cAMP analogues show preference for Site A and Site B,
respectively, while for type II protein kinase, both Sp- and Rp-
cAMP analogues exhibit preference for Site B.
To elucidate the importance of an intact cyclic phosphate
structure for the mechanism of inhibition of tumor cell prolif
eration and the induction of differentiation and to clarify how
important site selectivity for an analogue to Site B of protein
kinase type II is, we selected a set of new cAMP analogues
according to the test kit concept (19, 20). Systematic modifi
cations were chosen to (a) prevent hydrolysis of an analogue
and thus interference with metabolite formation and (b) find
out whether the biological data obtained in cell culture are
yielding the same sequence of biological activity as exhibited
by the kinetic binding data obtained for Sites A and B of protein
kinases, type I and II. The first aim was reached by substitution
of the exocyclic oxygen atom of cAMP and its analogues by
sulfur, yielding the diastereomers Sp- (axial substitution) and
Rp- (equatorial substitution). In addition these modifications
lead to a more pronounced site selectivity ratio in favor of
protein kinase type II Site B as compared with parent com
pounds cAMP (18).
We examined the effect of Sp and Rp forms of cAMP
analogues on the growth of HL-60 human promyelocytic leu
kemia and LS-174T human colon carcinoma cells in compari
son to that of the corresponding cyclophosphate analogue, and
the results were analyzed in relation to the binding affinity of
the analogue for and activation potency of protein kinase
isozymes.
MATERIALS AND METHODS
Chemicals. 8-Cl-cAMP was obtained from the National Cancer In
stitute, Division of Cancer Treatment, Bethesda, MD; 8-Br-cAMP was
obtained from Sigma Chemical Company (St. Louis, MO). Rp- and
Sp-cAMPS and -cAMPS analogues were synthesized as described pre
viously (17, 21, 22).
Cell Culture. HL-60 leukemic cells, obtained from the American
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Type Culture Collection (Rockville, MD), were grown in suspension
culture in RPMI 1640 supplemented with 10% heat-inactivated fetal
bovine serum, streptomycin (500 Mg/ml), penicillin (50 units/ml), and
glutamine (1 m\i) (Gibco, Grand Island, NY). For cell growth experi
ments, cells were seeded at the density of 2 x 105/ml and treated with
cAMP analogues 3 h after seeding. Cell counts were performed at
desired times on a Coulter Counter. Cell membrane integrity was
measured by trypan blue exclusion test, and cellular integrity was
measured by forward and side scatter with FACScan (Becton Dickinson,
San Jose, CA). Cell cycle distribution was determined by DNA content
analysis by propidium iodide staining as described previously (23).
Briefly, cells were fixed in 70% ethanol and stored at 4Â°Cbefore
analysis. Nuclear DNA were stained with propidium iodide, 50 Me/ml
in phosphate-buffered saline (pH 7.4), for 30 min at room temperature.
RNase was added to avoid double-helix RNA staining. The DNA
content of cells was analyzed by a FACScan flow cytometer coupled
with a Hewlett-Packard computer. Cell cycle data analysis was per
formed by a Cell-FIT program using the method of Dean (24) (Becton
Dickinson Immunocytometry Systems). Pulse area versus pulse width
gating was performed to exclude doublets from the G2-M region. For
each sample. 20,000 events were stored in list mode. Cell surface
antigen analysis was performed by flow cytometry with FACScan using
a panel of monoclonal antibodies reactive with either monocytic or
myeloid cells.
The LS-174T human colon carcinoma cell line (kindly provided by
J. Greiner, National Cancer Institute) was grown in Eagle's minimum
essential medium supplemented with 10% heat-inactivated fetal bovine
serum. Eagle's minimum essential medium nonessential amino acids,
20 mivi 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid, 2 mM glu
tamine, and penicillin-streptomycin (Gibco, Grand Island, NY); the
medium was changed every 48 h. For cell growth experiments, 2 x IO5
cells/60-mm dish were seeded; 24 h later the medium was removed,
and fresh medium and cAMP analogues using lOOx concentrated stock
solutions were added. At desired times, cell counts were performed in
duplicate on a Coulter Counter after harvesting cells with gentle
trypsinization.
Protein Kinase Assays. Protein kinase assays were performed by
measuring the transfer of 12Pfrom [-y-32P]ATPto Kemptide essentially
as described elsewhere (25).
RESULTS
Binding Affinities of Rp- and Sp-Phosphorothioate Analogues
of cAMP. The affinities of the cAMP analogues for Site A and
Site B of RI and RII were determined and standardized against
the relative affinity of cAMP for the same sites
KÃŒ(analogue) = K, cAMP
A, analogue
Dostman et al. (18) have shown that the substitution of sulfur
for the exocyclic axial oxygen (Sp) in general shows a slight
reduction in affinity for Site A of RI and a substantially higher
decrease in affinity for Site B of RI. The mean reduction in
affinity for RII, resulting from the Sp modification, is much
larger for Site A compared with Site B, which in general shows
a small decrease in affinity compared with the corresponding
cyclophosphate. As shown in Table 1, both Sp-8-Cl-cAMPS
and Sp-8-Br-cAMPS exhibited a greater decrease in affinity for
Site B (54- and 19-fold decrease, respectively) than Site A (15-
and 7-fold decrease, respectively) of RI, while showing prefer
ential decrease in affinity for Site A (22- and 37-fold decrease,
respectively) over Site B (1.9- and 3.1-fold decrease, respec
tively) of RII as compared with the corresponding cyclophos-
phate.
It has been shown (18) that the introduction of sulfur for the
equatorial exocyclic oxygen leads to a substantial decrease in
affinity for all four binding sites in both RI and RII. As shown
in Table l, Rp-8-Cl-cAMPS exhibited a 340- and 480-fold
decrease in affinity for Site A and B, respectively, of RI and a
180-fold decrease in affinity for Site A of RII as compared with
its cyclophosphate, 8-Cl-cAMP. However, Site B of RII showed
the smallest reduction (a 10-fold decrease) (Table 1). Thus, a
greater decrease in affinity for Site B than for Site A of RI and
a substantial decrease in affinity for Site A of RII with a small
decrease in the Site B affinity of RII are the common changes
resulting from the phosphorothioate modifications of 8-C1-
cAMP.
Table 2 shows the protein kinase activation constants (KJ of
these Sp- and Rp-phosphorothioate cAMP analogues. Sp-8-Cl-
cAMPS had an 11- and a 2.5-fold increase in the Ka for protein
kinase type I and type II, respectively, as compared with 8-C1-
cAMP. Rp-8-Cl-cAMPS was incapable of activating type I
protein kinase but was a weak agonist for type II protein kinase
(32-fold increase in the K* as compared with 8-Cl-cAMP).
Inhibition of Growth of III.-(ill Cells by Phosphorothioate
Derivatives of cAMP Analogues. The phosphorothioate deriv
atives of cAMP analogues were tested for their growth-inhibi
tory effect in HL-60 leukemia cells in comparison with their
homologous cyclophosphate derivatives. Fig. 1 displays the
dose-response curves for 3 days of treatment. 8-Cl-cAMP is a
potent growth inhibitor of HL-60 cells (5) (Fig. 1). Rp-8-Cl-
cAMPS, the exocyclic sulfur substitution in the equatorial
position of the cyclophosphate ring, was less inhibitory than 8-
Cl-cAMP but was more potent than Sp-8-Cl-cAMPS, which
has a sulfur substitution in the exocyclic axial oxygen position.
The growth-inhibitory effect of 8-Br-cAMP was low (<5%
growth inhibition at 20 ^M). However, a marked enhancement
of growth inhibition was observed with Sp-8-Br-cAMPS, which
has a sulfur substitution in the exocyclic axial oxygen position
(47% growth inhibition at 20 ÃŸMconcentration). The growth-
Table 1 Binding affinity ofSp- and Rp-phosphorothioate and cyclophosphate
analogues ofcAMP for cAMP receptor proteins, RI and RII
RI and RII are the regulatory subunits of cAMP-dependenl protein kinase
type I and type II, respectively. Site A and Site B are two distinct cAMP binding
sites (9, 10) on cAMP receptor proteins (RI and RII); the affinities of analogues
for Site A and Site B were determined by the measurement of kinetic constants
(inhibition constant, K,), and the values are expressed as the relative affinity A,(cAMPJ/A', (analogue), i.e., the ratio between the apparent inhibition constant for
cAMP and the analogue, as described (25).
RI RII
AnalogueSp-8-Cl-cAMPS
Rp-8-CI-cAMPS
Sp-8-Br-cAMPS"
8-Cl-cAMP*
8-Br-cAMPcSite
A0.18
0.0079
0.19
2.71
1.30SiteB0.037
0.0042
0.054
2.0
1.0Site
A0.0023
0.00028
0.003
0.051
0.11SiteB2.4
0.44
2.2
4.61
6.8
" From Dostmann et al. (18).
4 From Ally et al. (6).
' From 0greid et al. (26).
Table 2 Activation potency ofSp- and Rp-8-CI-cAMPS and 8-Cl-cAMPfor
protein kinase
Protein kinases types I (cAKI) and II (cAKII) were prepared from rabbit
skeletal muscle and bovine heart, respectively, as described (27). Ka is the concen
tration of cAMP or analogue sufficient for half-maximum activation of the protein
kinase (25). U.M.; unmeasurable.
AnalogueSp-8-Cl-cAMPS
Rp-8-CI-cAMPS
8-Cl-cAMP
cAMPActivation
cAKI2.5
x IO"7
U.M.1.8 x I0~8
4.0 x 10~8Constant
(K.)
cAKII2.5
x IO'7
3.2 x 10-Â«
1.0 x IO"7
8.0 x IO"8
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8-CI-cAMP
Rp-8-CI-cAMPS
Sp-8-Br-cAMPS
Sp-8-CI-cAMPS
1
Analogue ,,M
10 20
Fig. 1. Effect of cAMP analogue concentration on growth inhibition of HL-
60 leukemia cells. The growth inhibition was determined by counting cell number
at day 3 of culture time after treatment of cells with each analogue at given
concentrations at day zero (3 h after seeding) (see "Materials and Methods"). The
percentage of growth inhibition was obtained by comparing the growth of treated
cells to that of untreated control cells.
Table 3 Growth inhibition ofHL-60 human leukemia cells by phosphorothioate
derivatives ofcAMP analogues
The ICW values were determined from the dose-response cune experiments
like those shown in Fig. I and represent an average value obtained for each
analogue from two or more separate experiments carried out for 3 days or 6 days(see "Materials and Methods"). Initial cell number. 1 x lO'/dish. Typical numbers
of untreated control cells at day 3 and day 6 Â«ere 265.000 and 1.011.840,
respectively. 99% cell viability in treated and control cells.
Growth inhibition (IC50)
(MM)
AnalogueRp-8-CI-cAMPS
Sp-8-Cl-cAMPS
Sp-8-Br-cAMPS
8-Br-cAMP
8-CI-cAMPDay
316
100
28
1005Day
63
8
3
180.4
Table 4 Effect of Rp- and Sp-8-CI-cAMPS on cell cycle kinetics ofHL-60 cells
after 96 h of treatment
DNA content analysis by propidium iodide staining was performed; see "Ma
terials and Methods."
TreatmentControlRp-8-CI-cAMPS.
10MMRp-8-CI-cAMPS.
50MMRp-8-CI-cAMPS,
100MMSp-8-CI-cAMPS,
10MMSp-8-CI-cAMPS,
50MMSp-8-CI-cAMPS.
100MM8-CI-cAMP,
5MMN'-Benzyl-cAMP,
10 MM%G0-G,045.743.541.637.946.8465635.844.4%S4646.749.451.244.345.43552.846%G2-M8.39.89.010.9*8.98.69.011.39.6
" Coefficiency of variation of G0-G, = 2.1 ~ 2.9.
* Toxic effect.
6-fold more potent than 8-Br-cAMP.
Using a propidium iodide staining method (28, 29), we ex
amined whether the reduced cell proliferation observed in HL-
60 cells was due to a specific block in one phase of the cell
cycle. As shown in Table 4, the fractions of cells in G,, S, and
G2-M phases were not appreciably different between control
cells (untreated) and those treated with Rp- or Sp-8-CI-cAMPS
for 96 h.
Inhibition of Growth of LS-174T Human Colon Carcinoma
Cells by Phosphorothioates of cAMP Analogues. The growth-
inhibitory effect of phosphorothioates of cAMP and cAMP
analogues on LS-174T cells is shown in Table 5. The analogues
are listed in order from the most to the least potent for growth
inhibition. Rp-8-CI-cAMPS and Sp-8-Br-cAMPS exhibited the
greatest potency, Sp-6-SETcPMPS, Sp-8-CI-cAMPS, and Rp-
cAMPS showed moderate potency, and Sp-cAMPS and Sp-2-
Cl-cAMPS exhibited the least potency.
Rp-phosphorothioate of cAMP acts as an antagonist of
cAMP-dependent protein kinase activation (14). We examined
whether Rp-phosphorothioate would interfere with the growth-
inhibitory effect of homologous or heterologous cyclophosphate
derivative. Neither Rp-8-CI-cAMPS nor Rp-cAMPS interfered
with the growth-inhibitory effect of 8-CI-cAMP, and both ex
hibited an additive effect (Table 6).
Differentiation of HL-60 Leukemia Cells by Rp-8-CI-cAMPS.
We examined the effect of Rp- and Sp-8-CI-cAMPS on the
expression of differentiation markers in HL-60 cells to deter
mine if the growth-arrested HL-60 cells are more differentiated
than the untreated cells. Cells treated for 3 days with 50 MM
Rp-8-CI-cAMPS showing a 90% cell viability exhibited an
Table 5 Effect of phosphorothioate derivatives ofcAMP analogues on the growth
of LS-17 4T human colon carcinoma cells
The percentage growth inhibition values shown at 10 and 50 MManalogue
concentrations were determined from the dose-response curve experiments like
those shown in Fig. 1 and represent an average value obtained for each analogue
from two or more separate experiments (see "Materials and Methods"). Sp-6-
SET-cPMPS, Sp-6-ethylthiopurine-3';5'-monophosphorothioate; Sp-2-Cl-
cAMPS, Sp-2-chloroadenosine-3':5'-monophosphorothioate.
% Growth inhibition at
CompoundRp-8-CI-cAMPS
Sp-8-Br-cAMPS
Sp-6-SET-cPMPS
Sp-8-CI-cAMPS
Rp-cAMPS
Sp-2-Cl-cAMPS
Sp-cAMPS10
MM48
40
25
20
15
10
750
MM70
60
50
4035
25
15
Table 6 Additive growth inhibitory effect between phosphorothioate analogue and
8-CI-cAMP on LS-I74T human colon carcinoma cells
The percentage growth inhibition values represent an average value obtained
from two separate experiments carried out for 4 days. The analogues were added
at 24 h after seeding; see "Materials and Methods."
inhibitory effect of Rp- and Sp-cAMPS was negligible (<5% at
20 MM).
Table 3 shows IC50 values of cAMP analogues. The IC.so
values of all the analogues at day 6 were 10- to 12-fold lower
than those at day 3, indicating that the sensitivity of cells to
analogues increased with the length of time of treatment. The
IC50 values of day 6 indicate that the Rp- and Sp-phosphoro-
thioates of 8-CI-cAMP were 10- and 20-fold less potent, re
spectively, than 8-CI-cAMP. In contrast, Sp-8-Br-cAMPS ex
hibiting the IC50value identical to that of Rp-8-CI-cAMPS was
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Rp-8-CI-S 10MM
N6-benz
Sp-8-CI-S 100MM
c Rp-8-CI-S SODIVI
O)
N -benz
8-CI
Control
0 10 20 30 40 50 60 70 80 90 100 110
% Positive Cells
Fig. 2. Effect of phosphorothioate derivatives of cAMP analogue on the surface
marker expression of HL-60 cells. Control (untreated) cells and cells treated with
cAMP analogues for 96 h were analyzed for the expression of monocyte (Leu-
M3, HLA-DR, and Leu-15) and myeloid (Leu-Mi) specific antigens. The data
represent an average of three separate experiments. For each sample, 2x10"
cells were analyzed, and cell gating was performed using forward and side scatter.
D, Leu-M3; a, HLA-DR; D, Leu-15; â€¢¿Leu-Mi. Rp-8-CI-S, Rp-8-CI-cAMPS;
A"-ftcnr, N'-benzyl-cAMP:S>-S-O-S, Sp-8-Cl-cAMPS; 8-CI. 8-Cl-cAMP.
increase in the expression of monocyte-specific surface antigens
(3- and 2-fold increase of Leu-15 and HLA-DR, respectively,
over the control cell levels) as did 5 UM 8-Cl-cAMP (Fig. 2),
whereas treatment of cells with 100 MMSp-8-Cl-cAMPS had
no appreciable effect on the surface antigen expression (Fig. 2).
We have shown previously that 8-Cl-cAMP in combination
with N6-benzyl-cAMP demonstrates a synergism on cell differ
entiation (30). Rp-8-Cl-cAMPS in combination with N6-benzyl-
cAMP demonstrated the synergistic effect on the surface anti
gen expression (10- and 6-fold increase of Leu-15 and HLA-
DR, respectively, over the control cell levels) (Fig. 2). These
results show that Rp-8-Cl-cAMPS can mimic the effect of 8-
Cl-cAMP on the differentiation of HL-60 leukemia cells.
DISCUSSION
We have shown here that diastereomeric phosphorothioates
of cAMP analogues are potent inhibitors of the growth of
human cancer cell lines. Rp-8-Cl-cAMPS and Sp-8-Br-cAMPS,
both exhibiting IC50 3 MMin HL-60 leukemia cells, were the
two most potent growth inhibitors among the phosphoro
thioates tested.
The growth-inhibitory effect of Rp-8-Cl-cAMPS was about
10-fold lower than that of 8-Cl-cAMP but 3-fold greater than
that of Sp-8-Cl-cAMPS. The mechanism of action of Rp-8-Cl-
cAMPS in growth inhibition appears to be similar to that of 8-
Cl-cAMP. The growth inhibition by Rp-8-Cl-cAMPS did not
bring about any change in cell cycle phase as was shown with
8-Cl-cAMP (5), and Rp-8-Cl-cAMPS enhanced its growth-
inhibitory effect when added together with 8-Cl-cAMP and
increased differentiation in combination with N6-benzyl-cAMP
as was shown with 8-Cl-cAMP plus N6-benzyl-cAMP (30).
The striking potency of 8-Cl-cAMP in growth inhibition has
been related to its selective bifunctional effect on protein kinase
isozyme type I versus type II. It drastically down-regulates type
I protein kinase by dissociating it into its subunits while up-
regulating type II protein kinase in its holoenzyme form (6, 8).
The mechanism of action of 8-Cl-cAMP involves nuclear trans-
location of RII,j (6) and an increase in binding of nuclear
factor(s) to a synthetic cyclic AMP response element (31). It
has been proposed that 8-Cl-cAMP induces the nuclear trans-
location of type II protein kinase holoenzyme through binding
to Site B of RII (8). The selective nuclear translocation of type
II protein kinase but not type I protein kinase (6) has been
interpreted ( 13) to be due to the primary structure of RII subunit
which contains four positively charged amino acids 262KK R
265K (32), the nuclear location signal (33), near the Site B
cAMP binding site. It may be that the selective Site B binding
by 8-Cl-cAMP provides a controlled exposure of this sequence,
which might be the signal for regulating the transport of this
protein into the nucleus (34). Thus, preferential Site B binding
to RII could be the critical step in the effect of cAMP analogues
in growth regulation.
Previous work with diastereomeric phosphorothioate ana
logues of cAMP has demonstrated that the cyclic phosphate
position of the cAMP molecule and, in particular, the integrity
of the exocyclic oxygens, are important for determining the
binding affinity of the analogues and for initiating the molecular
events leading to dissociation of the holoenzyme (14-16). The
sulfur substitution of either exocyclic oxygen has been shown
to result in a significant loss in cAMP-binding affinity (18).
However, it was also found (18) that two cAMP binding sites
(Site A and B) contribute differently to this reduction. The
average reduction for the Sp modification is about 6-fold higher
for BI (Site B of RI) compared with AI (Site A of RI) and
approximately 5-fold higher for All (Site A of RII) compared
with BII (Site B of RII). For the Rp modifications, the reduction
is 2-fold higher for AI than for BI and 4-fold higher for All
than for BII. Thus, both Sp and Rp modifications bring about
only a small decrease in BII binding but a significant loss in
binding for other sites.
The present study demonstrated that the Sp and Rp modifi
cations of 8-Cl-cAMP affected BII affinity minimally while
exerting a great decrease in affinity for other sites (Table 1). It
appears, however, that rather than the absolute affinity of BII,
the ratio of affinity for BII/AII is important in the growth-
inhibitory effect of these analogues, since Rp-8-Cl-cAMPS,
which showed a greater potency in growth inhibition than Sp-
8-Cl-cAMPS, had the absolute affinity for BII much lower than
Sp-8-Cl-cAMPS (Table 1). Our results also showed that Rp-8-
Cl-cAMPS was incapable of activating type I protein kinase,
whereas Sp-8-Cl-cAMPS, despite its significant loss in affinity
for AI and BI, was capable of activating type I protein kinase
(Table 2). It appears from these results that activation of type
I protein kinase is not essential but facilitates growth inhibition
since Rp-8-Cl-cAMPS was more potent in growth inhibition
than Sp-8-Cl-cAMPS but was less potent than 8-Cl-cAMP.
Interestingly, Sp-8-Br-cAMPS was much more potent in
growth inhibition than 8-Br-cAMP, despite the fact that the
absolute binding affinities of this phosphorothioate to RI and
RII are much lower than the cyclophosphate (Table 1) (18).
The Sp modification of 8-Br-cAMP brought about enhance
ment of relative preference for Site A over Site B of RI and Site
B over Site A of RII (Table 1) (18). Thus, rather than the
absolute binding affinity, the changes in relative preference for
the specific site, especially Site B of RII, appear to be involved
in the growth-inhibitory potency of the analogue.
Our data showed that the Rp derivatives of cAMP or 8-C1-
cAMP exhibited not an antagonistic but an agonistic effect on
the growth inhibition. If only phosphorylation controlled by
cAMP would be responsible for the effects observed, at least
Rp-cAMPS, which is undoubtedly an antagonist of holoenzyme
dissociation (16), should not show inhibition of proliferation at
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all. The observation of growth inhibition by the Rp derivatives,
especially by those which have little or no potency in protein
kinase activation (i.e., dissociation of R subunit from C sub
unit), suggests a role for protein kinase holoenzyme or R
subunit independent of protein phosphorylation in the regula
tion of cell proliferation.
In general, Sp and Rp modifications render cAMP analogues
more lipophilic and resistant to hydrolysis by phosphodiester-
ase (35). Thus, phosphorothioate analogues may be superior
candidates over the cyclophosphates in practical applications
especially when the analogues demonstrate a greater potency
than homologous cyclophosphates as was the case for Sp-8-Br-
cAMPS. Further studies on the structure-function analysis of
phosphorothioate derivatives of cAMP would provide insights
into the mechanism of action of cAMP in growth regulation
and differentiation.
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